Adhera Therapeutics Inc (ATRX)

[Jose Chavez]

$ATRX “I am thrilled to welcome Andrew to our Board of Directors as we position to initiate Phase 2 clinical trials of MLR-1019 and MLR-1023 for Parkinson’s disease and Type 1 diabetes, respectively,” commented Andrew Kucharchuk, Chief Executive Officer at Adhera. “His decades of experience spanning the drug development spectrum and unprecedented understanding of these drug candidates will be invaluable in planned clinical trials, as will his business acumen and industry experience in identifying other drugs for accelerated development.”

“I am excited to join Adhera as a Director and look forward to lending my experience and network to assist in the next stage of development for some truly compelling therapeutics where there are clear areas of unmet medical need,” said Dr. Reaume. “Significant investment has gone into MLR-1019 and MLR-1023 already and we’re making strides expeditiously for what should be extremely valuable clinical research.”